Medical devices company Insulet Corp. (PODD) Wednesday reported fourth-quarter net loss of $10 million or $0.21 per share, compared with net loss of $14 million or $0.30 per share last year.
Revenues for the quarter were up 23% at $57.8 million, compared with $47 million a year ago.
Growth was due to enhanced customer base for the company's OmniPod Insulin Management System.
Analysts polled by Thomson Reuters estimated a loss of $0.22 per share on revenues of $59.02 million for the quarter. Analysts' estimates typically exclude special items.
Looking ahead to the first quarter, the company expects revenues of $56 million to $59 million, while analysts currently expect $60.48 million.
For fiscal year 2013, the company estimates revenues of $240 million to $255 million, while analysts currently estimate $262.92 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.